Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camp4 TherapeuticsCAMP +1.48%8 EV-to-OCF is -6.86 as of Sep. 09, 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Camp4 Therapeutics ranks better than 60.9% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Camp4 Therapeutics's Enterprise Value is $196.17 Mil.
Camp4 Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-28.59 Mil. Therefore, Camp4 Therapeutics's EV-to-OCF for today is -6.86.
The historical rank and industry rank for Camp4 Therapeutics's EV-to-OCF or its related term are showing as below:
CAMP'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.08 Med: -2.23 Max: 0.27
Current: -6.86
During the past 4 years, the highest EV-to-OCF of Camp4 Therapeutics was 0.27. The lowest was -8.08. And the median was -2.23.
CAMP's EV-to-OCF is ranked better than 60.9% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs CAMP: -6.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Camp4 Therapeutics's PE Ratio (TTM) for today is calculated as:
Camp4 Therapeutics's share price for today is $4.465.
Camp4 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.226.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Camp4 Therapeutics EV-to-OCF Related Terms
Camp4 Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Camp4 Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camp4 Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camp4 Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camp4 Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Camp4 Therapeutics's EV-to-OCF falls into.
Camp4 Therapeutics's current Enterprise Value is $196.17 Mil.
Camp4 Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camp4 Therapeutics (CAMP) has a EV-to-OCF of -6.86 as of Sep. 09, 2026. According to the industry distribution chart, Camp4 Therapeutics ranks #549 out of 1404 companies in the Biotechnology industry, placing it in the top 39.1%.
Is Camp4 Therapeutics' EV-to-OCF too high?
Camp4 Therapeutics' current EV-to-OCF is -6.86. Based on the distribution chart, Camp4 Therapeutics ranks #549 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' EV-to-OCF compare to NAGE and ALEC?
According to the Biotechnology industry distribution chart, Camp4 Therapeutics ranks #549 out of 1404 companies for EV-to-OCF. This puts Camp4 Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Camp4 Therapeutics's current EV-to-OCF is -6.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current EV-to-OCF of -6.86. The current EV-to-OCF is -6.86. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current EV-to-OCF is -6.86 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score
Get the complete analysis for CAMP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMP has been successfully added to your 
